Evidence map›Paper›PMID 40517253›Full record

ArticleBioData mining2025

Enhancing hepatopathy clinical trial efficiency: a secure, large language model-powered pre-screening pipeline.

Xiongbin Gui, Hanlin Lv, Xiao Wang, Longting Lv, Yi Xiao, Lei Wang

Abstract read
In one paragraph

Article in BioData mining, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. A comprehensive survey of AI agents in healthcare.Journal of biomedical informatics · 2026
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiongbin Gui *The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China.
Hanlin Lv *Institute of Biointellgence Technology, BGI Research, Wuhan, 430074, China.
Xiao WangInstitute of Biointellgence Technology, BGI Research, Wuhan, 430074, China.
Longting LvInstitute of Biointellgence Technology, BGI Research, Wuhan, 430074, China.
Yi XiaoThe First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China. 6128239@qq.com.
Lei WangInstitute of Biointellgence Technology, BGI Research, Wuhan, 430074, China. wanglei12@genomics.cn.

Funding

Second Batch of National TCM Clinical Research Base Construction Units 131 [2018]
6 · The paper itself

Abstract

backgroundRecruitment for cohorts involving complex liver diseases, such as hepatocellular carcinoma and liver cirrhosis, often requires interpreting semantically complex criteria. Traditional manual screening methods are time-consuming and prone to errors. While AI-powered pre-screening offers potential solutions, challenges remain regarding accuracy, efficiency, and data privacy.

methodsWe developed a novel patient pre-screening pipeline that leverages clinical expertise to guide the precise, safe, and efficient application of large language models. The pipeline breaks down complex criteria into a series of composite questions and then employs two strategies to perform semantic question-answering through electronic health records: (1) Pathway A, Anthropomorphized Experts' Chain of Thought strategy; and (2) Pathway B, Preset Stances within an Agent Collaboration strategy, particularly in managing complex clinical reasoning scenarios. The pipeline is evaluated on key metrics including precision, recall, time consumption, and counterfactual inference-at both the question and criterion levels.

resultsOur pipeline achieved a notable balance of high precision (e.g., 0.921, criteria level) and good overall recall (e.g., ~ 0.82, criteria level), alongside high efficiency (0.44s per task). Pathway B excelled in high-precision complex reasoning (while exhibiting a specific recall profile conducive to accuracy), whereas Pathway A was particularly effective for tasks requiring both robust precision and recall (e.g., direct data extraction), often with faster processing times. Both pathways achieved comparable overall precision while offering different strengths in the precision-recall trade-off. The pipeline showed promising precision-focused results in hepatocellular carcinoma (0.878) and cirrhosis trials (0.843).

conclusionsThis data-secure and time-efficient pipeline shows high precision and achieves good recall in hepatopathy trials, providing promising solutions for streamlining clinical trial workflows. Its efficiency, adaptability, and balanced performance profile make it suitable for improving patient recruitment. And its capability to function in resource-constrained environments further enhances its utility in clinical settings.

Indexed as

Electronic health recordsEligibility criteriaLiver diseaseNatural language processingPatient recruitment

Identifiers

PMID40517253
PMCPMC12167571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.